GGSK Read More GSK to buy Boston-based biopharma firm Nuvalent for $10.6bnJune 10, 2026 GSK said on Tuesday that it has agreed to buy Boston-based oncology-focused biopharmaceutical firm Nuvalent for $10.6bn (£7.9bn).…